1 From the University of California Irvine Medical Center, Irvine, and Fairview Hospital, Costa Mesa, California
Methylphenidate HCl (Ritalin) is usually given for the treatment of hyperactivity or attention deficit disorder (ADD) at 30 minutes to one hour before meals. This schedule is based on the assumption that, when taken with meals, its absorption or metabolism is altered. However, no behavioral or pharmacologic data exist to support this recommendation. Eleven patients with attention deficit disorder were tested to evaluate this hypothesis using a double-blind crossover design (methylphenidate with or before breakfast) with a placebo control condition. Parents' ratings, performance on a paired-associate learning test, and cortical auditoryevoked potentials were measured. All of these measurements showed clear differences between the placebo condition and conditions when medication was given. However, none of the measurements showed a significant difference between the conditions when methylphenidate was given with breakfast and the condition when methylphenidate was given 30 minutes before breakfast.
Key Words: hyperactivity attention deficit disorder methylphenidate
Submitted on May 10, 1982
Accepted on October 15, 1982
This article has been cited by other articles:
![]() |
R. Bussing, M. Fernandez, M. Harwood, Wei Hou, C. W. Garvan, S. M. Eyberg, and J. M. Swanson Parent and Teacher SNAP-IV Ratings of Attention Deficit Hyperactivity Disorder Symptoms: Psychometric Properties and Normative Ratings From a School District Sample Assessment, September 1, 2008; 15(3): 317 - 328. [Abstract] [PDF] |
||||
![]() |
M. A. Serra-Pinheiro, P. Mattos, and M. Angelica Regalla Inattention, Hyperactivity, and Oppositional- Defiant Symptoms in Brazilian Adolescents: Gender Prevalence and Agreement Between Teachers and Parents in a Non-English Speaking Population J Atten Disord, September 1, 2008; 12(2): 135 - 140. [Abstract] [PDF] |
||||
![]() |
S. B. Wigal and T. L. Wigal The laboratory school protocol: its origin, use, and new applications. J Atten Disord, August 1, 2006; 10(1): 92 - 111. [Abstract] [PDF] |
||||
![]() |
J. M. Swanson Flawed Attention-Deficit/Hyperactivity Disorder Medication Comparison: In Reply Pediatrics, October 1, 2004; 114(4): 1132 - 1133. [Full Text] [PDF] |
||||
![]() |
R. S. Shalev and V. Gross-Tsur Developmental Dyscalculia and Medical Assessment J Learn Disabil, February 1, 1993; 26(2): 134 - 137. [Abstract] [PDF] |
||||
![]() |
M. D. Rapport Introduction: Treating Children with Attention-Deficit Hyperactivity Disorder Behav Modif, April 1, 1992; 16(2): 155 - 163. |
||||
![]() |
S. R. Forness, D. P. Cantwell, J. M. Swanson, G. L. Hanna, and D. Youpa Differential Effects of Stimulant Medication on Reading Performance of Boys With Hyperactivity With and Without Conduct Disorder J Learn Disabil, May 1, 1991; 24(5): 304 - 310. [Abstract] [PDF] |
||||
![]() |
J. M. Swanson, D. Cantwell, M. Lerner, K. McBurnett, and G. Hanna Effects of Stimulant Medication on Learning in Children with ADHD J Learn Disabil, April 1, 1991; 24(4): 219 - 230. [Abstract] [PDF] |
||||
![]() |
K. K.S. Voeller Clinical Management of Attention Deficit Hyperactivity Disorder J Child Neurol, January 1, 1991; 6(1_suppl): S51 - S67. [Abstract] [PDF] |
||||
![]() |
L. K. Laird and J. J. Saklad Attention-Deficit Hyperactivity Disorder Journal of Pharmacy Practice, January 1, 1990; 3(4): 241 - 251. [Abstract] [PDF] |
||||